Minjuvi Gains Accelerated Funding in Ontario for Relapsed/Refractory Follicular Lymphoma Incyte announced that Minjuvi (tafasitamab), in combination with R² (lenalidomide and rituximab), is now funded...
Minjuvi Gains Accelerated Funding in Ontario for Relapsed/Refractory Follicular Lymphoma Incyte announced that Minjuvi (tafasitamab), in combination with R² (lenalidomide and rituximab), is now funded...